title: Effect of Telmisartan on local cardiovascular oxidative stress in mouse under chronic intermittent hypoxia condition.
abstract: OBJECTIVE
  The objective of this study is to explore the protective effect of an angiotensin receptor blocker (ARB) on local cardiovascular angiotensin II (AngII) and oxidative stress markers such as malondialdehyde (MDA), NADPH oxydase p47(phox), and 8-hydroxy-2'-deoxyguanosine/8-hydroxyguanosine (8-OHdG/8-OHG) of mice that had chronic intermittent hypoxia (CIH).
  
  
  METHODS
  Thirty-two healthy male C57B6J mice were randomly divided into four groups: CIH (12 weeks of CIH), ARB (CIH+Telmisartan), air control (room air delivery), and blank control (no treatment). AngII, p47(phox), and 8-OHdG/8-OHG were detected in mouse cardiocytes by immunohistochemistry. MDA was measured with the thiobarbituric acid method.
  
  
  RESULTS
  The highest AngII levels occur in the ARB treatment group (P < 0.05), followed by the CIH group (which was higher than the two control groups; P = 0.000). The levels of p47(phox) were statistically higher in the CIH group than in the other groups (P = 0.000) and lower in the ARB group (but still higher than in the two control groups, P = 0.000). The levels of 8-OHdG/8-OHG were the highest in the CIH group (P < 0.05), followed by the ARB group (which was higher than the two control groups, P = 0.000). The levels of MDA in the myocardial homogenate of mice were the highest in the CIH group (P = 0.000).
  
  
  CONCLUSIONS
  Based on the above results, it can be concluded that Telmisartan may protect mouse cardiocytes from oxidative stress damage due to CIH.
authors.affiliation: Pneumology Department of the Second Affiliated Hospital of Fujian Medical University, Quanzhou, China. zeng_yi_ming@126.com
authors.forename: Wan-Yu
authors.initials: WY
authors.lastname: Wang
authors.forename: Wan-Yu
authors.initials: WY
authors.lastname: Wan
authors.forename: Yi-Ming
authors.initials: YM
authors.lastname: Zeng
authors.forename: Xiao-Yang
authors.initials: XY
authors.lastname: Chen
authors.forename: Yi-Xiang
authors.initials: YX
authors.lastname: Zhang
mesh_terms: D000284:Administration, Oral; D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology*; D000818:Animals; D001562:Benzimidazoles / Q000494:pharmacology*; D001565:Benzoates / Q000494:pharmacology*; D015415:Biomarkers / Q000032:analysis; D002908:Chronic Disease; D004195:Disease Models, Animal; D000860:Hypoxia / Q000503:physiopathology*; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D009206:Myocardium / Q000473:pathology; D019255:NADPH Oxidases / Q000502:physiology; D018384:Oxidative Stress / Q000187:drug effects* / Q000502:physiology*; D012016:Reference Values; D020181:Sleep Apnea, Obstructive / Q000503:physiopathology*; D000077333:Telmisartan
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D001562:Benzimidazoles; D001565:Benzoates; D015415:Biomarkers; D019255:NADPH Oxidases; D000077333:Telmisartan